Abstract. Tetramethylpyrazine (TMP), a bioactive compound isolated from the Chinese herb, Ligusticum wallichii Franchat, has been reported to play a protective role in cardiac diseases. However, the cellular and molecular mechanisms behind the protective effects of TMP on the heart remain to be elucidated. In this study, we aimed to determine the effects of TMP on angiotensin II (Ang II)-induced hypertrophy in neonatal rat cardiomyocytes and its possible mechanisms of action. In addition, we investigated whether TMP regulates tumor necrosis factor-α (TNF-α) secretion and expression. We found that TMP significantly inhibited the Ang II-induced hypertrophic growth of neonatal cardiomyocytes, as evidenced by the decrease in Further experiments revealed that Ang II increased the level of the phosphorylated form of the transcription factor, nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), as well as NF-κB-DNA binding activity in the cardiomyocytes; treatment with TMP significantly inhibited the Ang II-induced activation of NF-κB. Furthermore, the inhibition of NF-κB by the specific inhibitor, pyrrolidine dithiocarbamate (PDTC), markedly attenuated the Ang II-induced increase in [ 3 H] leucine incorporation, β-MHC mRNA expression and TNF-α protein secretion. Our findings suggest that TMP inhibits Ang II-induced cardiomyocyte hypertrophy and TNF-α production through the suppression of the NF-κB pathway, which may provide new insight into the mechanisms underlying the protective effects of TMP in heart diseases.
Introduction
Cardiac hypertrophy, an increase in cardiomyocyte size, has been recognized as an independent risk factor for future cardiovascular morbidity and mortality (1) . Angiotensin II (Ang II) has been implicated in cardiomyocyte hypertrophy (2) . The hypertrophic effects of Ang II are mediated by several intracellular signaling pathways, including the nuclear factor κ-light-chainenhancer of activated B cells (NF-κB) pathway (3) . NF-κB has been validated as a therapeutic target for the prevention of cardiac hypertrophy and heart failure (4) .
Tetramethylpyrazine (TMP, molecular structure shown in Fig. 1C ), a biologically active ingredient isolated from the Chinese herb, Ligusticum wallichii Franchat, has been widely used for the treatment of ischemic cardiovascular diseases (5-7). Its pharmacological functions include anti-ischemic (7), anti-inflammatory (8) , antioxidant (9) and anti-arrhythmic properties (7) . The anti-inflammatory properties of TMP have been reported to involve the suppression of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (8) . These cytokines have been implicated in the pathogenesis of cardiac hypertrophy (10, 11) . However, the effects of TMP on cardiac hypertrophy and the expression of TNF-α in cardiomyocytes remain unclear.
In light of these observations, we hypothesized that TMP inhibits Ang II-induced cardiomyocyte hypertrophy, and that the modulation of the NF-κB pathway, if present, is responsible for the anti-hypertrophic effects of TMP. Furthermore, in this study, we determined whether TMP regulates the Ang II-stimulated secretion and expression of TNF-α in neonatal rat cardiomyocytes. (12) with minor modifications. Briefly, ventricles were excised from 1-to 3-dayold neonatal Sprague-Dawley rats, which were decapitated to isolate the hearts. Subsequently, the ventricular tissues were minced into ~1 mm 3 sections and digested using 0.1% trypsin (Sigma-Aldrich) and 0.1% collagenase type II (Sigma-Aldrich) in D-Hanks solution and agitated for 7 min at 37˚C to dissociate the cardiomyocytes. The remaining tissues were transferred into a fresh enzyme solution and allowed to dissociate for 7 min. This digestion was repeated 5 times. Cell suspensions were collected, centrifuged (5 min, 60 x g) and resuspended in DMEM supplemented with 5% fetal bovine serum. Dissociated cells were pre-plated for 1 h at 37˚C to selectively remove nonmyocytes. Non-adherent cardiomyocytes (>90% purity) were plated on 6-well culture plates at a density of 2x10 5 cells/ml DMEM containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Following incubation for 48 h at 37˚C 5% CO 2 , the medium was replaced by fetal bovine serum-free medium and the cells were starved for 10 h prior to the addition of drugs. The cardiomyocytes were subsequently incubated for a further 24 h with the vehicle (control) or with 0.1 µM Ang II in the presence or absence of TMP or NF-κB inhibitor at the indicated concentrations.
Materials and methods

Reagents
Protein synthesis. Protein synthesis was determined by measuring the incorporation of [ 3 H]leucine incorporation into acid-insoluble protein, which is commonly used as evidence of hypertrophy (13) . The cells were treated for 24 h in the presence or absence of 0.1 µM Ang II and TMP (0.001-1.0 mM). RNA isolation and real-time PCR. Total RNA was isolated from the cultured neonatal cardiomyocytes using TRIzol reagent (Invitrogen Corp.) according to the manufacturer's instructions. Subsequently, ~2 µg of total RNA was reverse transcribed with ReverTra Ace reverse Transcriptase (Toyobo Co., Ltd., Osaka, Japan). The RT reaction product was heated at 95˚C to terminate the reaction. The expression of β-MHC, TNF-α and GAPDH mRNA was examined by real-time PCR using a SYBR-Green dye. The primers used were as follows: rat β-MHC sense, 5'-TAACCCGAGGCAAGCTCACA-3' and antisense, 5'-CACAATCATGCCGTGCTGAC-3' (product size, 120 bp); rat TNF-α sense, 5'-GCCAATGGCATGGATC TCAAAG-3' and antisense, 5'-CAGAGCAATGACTCCA AAGT-3' (product size, 357 bp); rat GAPDH sense, 5'-CTCAT GACCACAGTCCATGCCATC-3' and antisense, 5'-CGGAA GGCCATGCCAGTGAG-3' (product size, 182 bp). Real-time PCR was performed on an iCycler iQ Real-Time Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Amplification involved 1 cycle at 94˚C for 3 min for initial denaturation followed by 40 cycles of denaturation for 30 sec at 94˚C, annealing for 30 sec at 60˚C and extension for 45 sec at 72˚C. All reactions were performed in triplicate and GAPDH served as an internal control. The results were quantified as Ct values, where Ct is defined as the threshold cycle of PCR at which the amplified product is first detected and the values are expressed as the ratio of the target gene to the control. The size of the PCR products was confirmed by electrophoresis on 2% agarose gels with ethidium bromide staining.
Measurement of TNF-α in the culture medium.
At the end of the drug treatment, the culture supernatants were harvested, and the level of TNF-α protein was measured using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions.
Western blot analysis. To elucidate the mechanisms through which TMP exerts its effects on hypertrophic cardiomyocytes, we examined the protein expression of NF-κB (p-NF-κB p65).
At the end of the drug treatment, total protein was extracted from the cardiomyocytes using the Protein Extraction kit (Beyotime Institute of Biotechnology, Beijing, China). Protein concentration was measured using the BCA Protein assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein extract were analyzed by 10% SDS-PAGE and electrotransferred onto an immobilon-P transfer membrane (Millipore, Bedford, MA, USA). The membrane was probed overnight at 4˚C with primary antibodies against NF-κB p65 and the phosphorylated form of NF-κB p65 (p-NF-κB p65) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) Following incubation with HRP-linked rabbit IgG antibody, the signal was visualized using the ECL Plus system (Beyotime Institute of Biotechnology), according to the manufacturer's instructions. Immunoblotting signals were quantified using Image J software [National Institutes of Health (NIH), Bethesda, MD, USA].
ELISA-based NF-κB transcription factor activity assay. The cardiomyocytes were treated with the same methods mentioned above, and then nuclear protein was extracted using the Nuclear Protein Extraction kit (Beyotime Institute of Biotechnology) and quantified using the BCA Protein assay kit mentioned above according to the manufacturer's instructions. Nuclear extracts were frozen in liquid N 2 and stored at -70˚C until use.
ELISA-based NF-κB transcription factor activity assay was performed using a Trans-AM NF-κB p65 transcription factor assay kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions. The level of nuclear NF-κB p65 was expressed as the absorbance at 450 nm (A450).
Statistical analysis.
All values are expressed as the means ± SEM. Statistical analyses were performed using unpaired Student's t-tests and one-way ANOVA where appropriate. A P-value <0.05 was considered to indicate a statistically significant difference. TMP prevents Ang II-induced NF-κB activation and translocation. We then investigated whether TMP regulates the Ang II-induced activation of the NF-κB pathway. As shown in Fig. 2 , treatment with Ang II for 24 h increased the protein levels of phosphorylated NF-κB p65 ( Fig. 2A) and the NF-κB-DNA binding activity (Fig. 2B) in the cardiomyocytes. Conversely, TMP prevented these effects induced by Ang II.
Results
TMP attenuates the
Anti-hypertrophic effects of TMP are associated with inhibition of the NF-κB pathway. To investigate whether the modulation of NF-κB pathway is responsible for the anti-hypertrophic effects of TMP, the NF-κB inhibitor, PDTC (100 µM), was used in this study. The cardiomyocytes were treated with Ang II (0.1 µM) for 24 h in the presence or absence of PDTC (100 µM). First, we determined the specificity of the inhibitor by western blot analysis. As shown in Fig. 3 , the NF-κB inhibitor markedly inhibited the Ang II-induced upregulation of phosphorylated NF-κB p65 (Fig. 3A) and the NF-κB-DNA binding activity (Fig. 3B) in the cardiomyocytes. In addition, the NF-κB inhibitor significantly inhibited the Ang II-induced cardiomyocyte hypertrophy, as evidenced by the decrease in [ 3 H]leucine incorporation (Fig. 4A ) and β-MHC mRNA expression (Fig. 4B) . Of note, PDTC alone had no effect on [ (Fig. 5A ) and protein secretion of TNF-α (Fig. 5B) , whereas TMP (1.0 mM) markedly inhibited these effects induced by Ang II. In addition, we found that compared to treatment with Ang II (0.1 µM) alone, the combined treatment of Ang II and PDTC (100 µM) significantly reduced the mRNA expression (Fig. 6A ) and protein secretion (Fig. 6B ) of TNF-α. Thus, TMP inhibited the Ang II-induced upregulation of TNF-α mRNA expression and protein secretion through the inhibition of the NF-κB pathway.
Discussion
The present study demonstrated that Ang II induced hypertrophic growth in neonatal cardiomyocytes, as evidenced by the increase in [ 3 H]leucine incorporation and β-MHC mRNA expression, which was significantly inhibited by treatment with TMP. Ang II induced NF-κB activation in the cardiomyocytes, whereas TMP decreased the levels of phosphorylated NF-κB. In addition, TMP inhibited the Ang II-stimulated mRNA expression and protein secretion of TNF-α in the cardiomyocytes, which was dependent on NF-κB.
Previous in vivo and in vitro studies support an important protective role of TMP (also known as ligustrazine) in cardiac diseases. First, TMP exerts vasodilatory effects by affecting the release of the vasoactive substances, thromboxane A2 (TXA 2 ) and prostacyclin (PGI 2 ), in isolated rat hearts, which may contribute to its beneficial effects in myocardial hypoxia or ischemia (14) . Second, TMP has been reported to reduce ischemia-induced ventricular arrhythmias (7), and the possible ionic mechanism for the anti-arrhythmic effect of TMP may involve its regulation of cardiomyocyte ion channels, such as L-type Ca 2+ channels (15) . Third, TMP has also been suggested as a potent antioxidant with efficacy in lipid peroxidationinduced heart toxicity (9). Furthermore, the protective role of TMP in burn-induced myocardial injury has been suggested to be associated with its inhibition of the release of TNF-α (16) . Although a recent study demonstrated that TMP exerts protective effects against dilated cardiomyopathy in transgenic mice (17) , the role of TMP in cardiac hypertrophy and its possible mechanisms of action remain unknown. In the present study, we first demonstrated that TMP inhibited Ang II-induced cardiomyocyte hypertrophy in vitro and the release of the proinflammatory cytokine, TNF-α, in cardiomyocytes.
The underlying molecular mechanisms of cardiac hypertrophy are extremely complex and involve intricate interactions of multiple signaling pathways. Of these, the involvement of the NF-κB pathway in the pathogenesis of cardiac hypertrophy has been well established (4, 18, 19) . Under pathological conditions, a number of hypertrophic factors, such as Ang II (20) and isoproterenol (21) activate the NF-κB pathway in cardiomyocytes. In unstimulated cells, the major form of NF-κB complexes is an inactive heterodimer composed of the p50 and p65 subunits and is sequestered into the cytoplasm through its interaction with specific inhibitory proteins, such as IκB (22) . Extracellular stimuli that activate NF-κB induce the rapid phosphorylation of IκB and subsequently, the dissociation of NF-κB from IκB. Once activated, activated NF-κB translocates to the nucleus, where it acts as a transcription factor by binding to regulatory DNA sequences, triggering hypertrophic gene expression (23) . The inhibition of NF-κB has been demonstrated to exert antihypertrophic effects in cardiomyocytes (4, 24) . In the present study, we therefore hypothesized that the inhibition of the NF-κB pathway is the molecular basis for the anti-hypertrophic effects of TMP. Our results revealed that treatment with TMP markedly suppressed the Ang II-induced secretion of phos- phorylated NF-κB p65 in the cardiomyocytes; the inhibition of NF-κB by the specific inhibitor, PDTC, significantly inhibited Ang II-induced hypertrophy; thus, the inhibition of NF-κB may be one of the mechanisms behind the anti-hypertrophic effects of TMP. However, the mechanisms by which TMP inhibits the NF-κB pathway remain unknown. Thus, further studies are required to clarify this issue. Although the direct pro-hypertrophic effects of TNF-α have been well documented (10, (25) (26) (27) , there is also evidence to suggest that TNF-α mediates the effects of other hypertrophic factors in an autocrine or paracrine fashion. Previous studies have shown that Ang II increases the expression of TNF-α in cardiomyocytes (28) . In the present study, we also found that Ang II induced TNF-α secretion and expression in neonatal cardiomyocytes. In TNF-α knockout mice, a previous study demonstrated that TNF-α plays a role in mediating chronic Ang II-induced effects on blood pressure and cardiac hypertrophy (29) . Taken together, these data suggest that the autocrine release of TNF-α mediates the hypertrophic effects of Ang II. In this study, treatment with TMP attenuated the Ang II-induced secretion and expression of TNF-α, which may also contribute to the anti-hypertrophic effects of TMP.
In conclusion, the present study investigated the therapeutic effects of TMP on myocardial hypertrophy induced by Ang II. To our knowledge, our results demonstrate for the first time that TMP prevents Ang II-induced hypertrophy in neonatal cardiomyocytes, which is attributed to its inhibition of the NF-κB pathway and TNF-α secretion in cardiomyocytes (the proposed mechanisms underlying the anti-hypertrophic effects of TMP are illustrated in Fig. 7 ). These findings raise the possibility of developing TMP as a therapeutic drug for cardiac hypertrophy.
